



# Pro-arrhythmia metrics from in-silico action potential models

Gary Mirams


Computational Biology,  
University of Oxford

CiPA Update Meeting  
11<sup>th</sup> December 2014

# Where does in-silico pro-arrhythmia evaluation fit into CiPA?




Throughput

Cost



Simulation Predictions of:

- SC-CM recordings
- QT
- *Arrhythmic risk*





Uncertainty

Accuracy

# Possible Metrics: cell level

- Repolarisation delay



- Pros:


- Correlation with risk is understood as per QT
- Validation of mechanistic predictions is straightforward
  - [ish - see recent Mirams et al. 2014 JPTM paper]

- Cons

- APD/QT prolongation is not equal to pro-arrhythmic risk

# It's not all about hERG: Ranolazine

90% block of  $I_{Kr}$



90% block of  $I_{Kr}$  + 50% block of  $I_{pNa}$

Noble & Noble, *Heart*, **92**, iv1-5, (2006)

see also Moreno et al., *Circ. Res.* (2013)

# Can we do better than QT?

*J. Physiol.* (1969), **200**, pp. 255–265

255

*With 4 text-figures*

*Printed in Great Britain*


THE MECHANISM OF  
OSCILLATORY ACTIVITY AT LOW MEMBRANE POTENTIALS  
IN CARDIAC PURKINJE FIBRES

BY O. HAUSWIRTH,\* D. NOBLE AND R. W. TSIEN†

*From the University Laboratory of Physiology, Oxford*


# Possible Metrics: cell level

- Quantify 'Repolarization Reserve'
- AP Triangulation
- Reverse-use dependence (Hondegghem et al. Circulation, 2001)
- Beat-to-beat stability (Heijman et al. PLoS Comp. Biol., 2013)
- 'EAD tendency'
- 'DAD tendency'
- Substrates and triggers
  
- Pros:
  - more mechanistic links to TdP
  - different ways' to be captured
- Cons:
  - validation of the mechanistic p
  - experiments that would be nee



# EAD Tendency


EAD-promoting  
intervention



# Possible Metrics: tissue and organ level

- Dispersion of repolarization
- Vulnerable period (see Starmer papers)
- Spiral Wave induction and breakup (e.g. Moreno et al. 2011)

**G** 1  $\mu$ M flecainide, 80 BPM, S1 - S2 = 600 ms



**H** 10  $\mu$ M flecainide, 80 BPM, S1 - S2 = 580 ms



- Higher level integration could be the key to some types of arrhythmias.
- Cons:
  - More unknowns in terms of tissue coupling, heterogeneity, fibre directions, patient specificity. Validation of the mechanisms behind these predictions is very difficult



# Challenges

- What would success look like?
  - Limited number of CiPA ref compounds. 3 risk categories
- Characterisation and variability of SC-CM electrophysiology
- Capturing ion channel ‘drug kinetics’ is very complicated
  - We’ll only really know if it helps once we’ve tried it
- Will high-throughput machines be accurate enough to capture what can be a delicate balance of current block?

(Elkins et al. 2013)
- **Quantify uncertainty** in predictions

# Putting the 'C' in CiPA...

- Lots of possible markers – perhaps we shouldn't be looking for one...
- Patient subgroups
  - Genetic:
    - Sex
    - Ion channel mutations
    - etc.
  - Disease:
    - Under various heart failure and ischaemic electrophysiology situations
- Co-administration of drugs
- Risk assessment for the patient not the pill

# Acknowledgements

---

- Denis Noble
- Blanca Rodriguez
- Colleen Clancy
- David Gavaghan
- Beth McMillan

## Website:

[www.cs.ox.ac.uk/people/gary.mirams](http://www.cs.ox.ac.uk/people/gary.mirams)

Twitter: @GaryMirams

**wellcome**trust  
Fellow



**EPSRC**  
Engineering and Physical Sciences  
Research Council

